S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)
S&P 500   5,069.76 (-0.17%)
DOW   38,949.02 (-0.06%)
QQQ   435.27 (-0.53%)
AAPL   181.42 (-0.66%)
MSFT   407.72 (+0.06%)
META   484.02 (-0.62%)
GOOGL   136.38 (-1.80%)
AMZN   173.16 (-0.22%)
TSLA   202.04 (+1.16%)
NVDA   776.63 (-1.32%)
NIO   5.44 (-6.05%)
AMD   176.54 (-0.82%)
BABA   74.60 (-3.96%)
T   16.96 (+0.77%)
F   12.30 (+2.50%)
MU   89.71 (-2.33%)
CGC   3.36 (-4.82%)
GE   155.62 (+1.06%)
DIS   110.81 (+1.27%)
AMC   5.00 (+3.95%)
PFE   27.06 (+0.59%)
PYPL   60.25 (+0.15%)
XOM   104.37 (+0.33%)

Oramed Pharmaceuticals (ORMP) Competitors

$3.41
-0.17 (-4.75%)
(As of 02/28/2024 ET)

ORMP vs. NKTR, ATOS, GBIO, RVPH, ANIX, NVCT, IMAB, NGM, RNAC, and MCRB

Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include Nektar Therapeutics (NKTR), Atossa Therapeutics (ATOS), Generation Bio (GBIO), Reviva Pharmaceuticals (RVPH), Anixa Biosciences (ANIX), Nuvectis Pharma (NVCT), I-Mab (IMAB), NGM Biopharmaceuticals (NGM), Cartesian Therapeutics (RNAC), and Seres Therapeutics (MCRB). These companies are all part of the "pharmaceutical preparations" industry.

Oramed Pharmaceuticals vs.

Oramed Pharmaceuticals (NASDAQ:ORMP) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk.

Nektar Therapeutics received 312 more outperform votes than Oramed Pharmaceuticals when rated by MarketBeat users. However, 74.82% of users gave Oramed Pharmaceuticals an outperform vote while only 70.77% of users gave Nektar Therapeutics an outperform vote.

CompanyUnderperformOutperform
Oramed PharmaceuticalsOutperform Votes
315
74.82%
Underperform Votes
106
25.18%
Nektar TherapeuticsOutperform Votes
627
70.77%
Underperform Votes
259
29.23%

Oramed Pharmaceuticals has a beta of 1.83, suggesting that its stock price is 83% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the S&P 500.

Oramed Pharmaceuticals has higher earnings, but lower revenue than Nektar Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oramed Pharmaceuticals$2.70M50.95-$36.56M-$0.41-8.32
Nektar Therapeutics$92.06M1.49-$368.20M-$1.56-0.46

Nektar Therapeutics has a net margin of -332.73% compared to Oramed Pharmaceuticals' net margin of -747.02%. Oramed Pharmaceuticals' return on equity of -10.90% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oramed Pharmaceuticals-747.02% -10.90% -9.23%
Nektar Therapeutics -332.73%-80.44%-35.10%

Nektar Therapeutics has a consensus price target of $3.33, suggesting a potential upside of 362.96%. Given Nektar Therapeutics' higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oramed Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Nektar Therapeutics
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Nektar Therapeutics had 8 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 11 mentions for Nektar Therapeutics and 3 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.68 beat Nektar Therapeutics' score of 0.59 indicating that Oramed Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oramed Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nektar Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

5.8% of Oramed Pharmaceuticals shares are owned by institutional investors. Comparatively, 82.2% of Nektar Therapeutics shares are owned by institutional investors. 12.0% of Oramed Pharmaceuticals shares are owned by company insiders. Comparatively, 3.1% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Oramed Pharmaceuticals beats Nektar Therapeutics on 9 of the 17 factors compared between the two stocks.


Get Oramed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORMP vs. The Competition

MetricOramed PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$137.56M$6.52B$4.96B$7.45B
Dividend YieldN/A2.64%2.90%3.88%
P/E Ratio-8.3210.36225.8416.90
Price / Sales50.95171.933,032.6664.65
Price / CashN/A19.7194.9854.63
Price / Book0.884.814.474.66
Net Income-$36.56M$152.42M$112.56M$210.60M
7 Day Performance6.23%6.86%5.15%2.49%
1 Month Performance46.98%14.30%13.01%4.77%
1 Year Performance62.38%6.75%11.94%7.50%

Oramed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKTR
Nektar Therapeutics
4.3942 of 5 stars
$0.66
-7.0%
$3.00
+352.1%
-46.0%$126.60M$92.06M-0.43216Upcoming Earnings
Short Interest ↓
News Coverage
Gap Up
ATOS
Atossa Therapeutics
0.8445 of 5 stars
$1.02
+1.0%
$4.50
+341.2%
+35.0%$127.81MN/A-4.2511
GBIO
Generation Bio
3.886 of 5 stars
$1.97
-7.5%
$8.56
+334.4%
-41.4%$130.18MN/A-0.99150Upcoming Earnings
RVPH
Reviva Pharmaceuticals
2.4466 of 5 stars
$4.39
+2.1%
$16.75
+281.5%
-14.7%$122.57MN/A-2.6310
ANIX
Anixa Biosciences
2.5332 of 5 stars
$3.86
-4.7%
$10.50
+172.0%
-15.7%$122.40M$210,000.00-12.064Short Interest ↓
NVCT
Nuvectis Pharma
1.5819 of 5 stars
$7.03
-6.5%
$21.00
+198.7%
-11.2%$121.81MN/A-4.6911Upcoming Earnings
IMAB
I-Mab
3.5695 of 5 stars
$1.64
-4.1%
$19.00
+1,058.5%
-56.3%$132.35M$13.81M0.00228Short Interest ↓
NGM
NGM Biopharmaceuticals
4.4553 of 5 stars
$1.61
+5.2%
$4.75
+195.0%
-64.3%$133.18M$55.33M-0.88239Analyst Report
News Coverage
Gap Down
RNAC
Cartesian Therapeutics
0.5856 of 5 stars
$0.74
-6.3%
N/AN/A$120.14M$110.78M-3.3764Positive News
MCRB
Seres Therapeutics
3.8623 of 5 stars
$1.04
-1.0%
$13.20
+1,169.2%
-77.0%$134.43M$7.13M-0.93431Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:ORMP) was last updated on 2/28/2024 by MarketBeat.com Staff